Dynamic Changes of Plasma sCD27 Levels and Survival of Hepa-tocellular Carcinoma Patients Receiving Immune Checkpoint In-hibitor Therapy
[Objective]To analyze the relationship between change of plasma soluble CD27(sCD27)level and the survival of patient with hepatocellular carcinoma(HCC)receiving immune checkpoint inhibitor(ICIs)therapy.[Methods]Clinic al data of 72 HCC patients treated with ICIs from October 2017 to March 2022 were retrospectively analyzed.Plasma levels of sCD27,soluble programmed cell death pro-tein 1(sPD-1),and soluble programmed cell death ligand 1(sPD-L1)were detected by multi-bead im-munoassays before(baseline)and 6 weeks after immunotherapy.Patients were followed,and the overall survival(OS),time to progression(TTP)and progression-free survival(PFS)were documented.The cor-relation between the changes of sCD27 level(Δ-sCD27)and the OS,TTP and PFS of patients were ana-lyzed by univariate and multivariate Cox regression analysis,and the prognostic value of Δ-sCD27 in HCC was analyzed by Kaplan-Meier curve.[Results]Univariate and multivariate Cox regression analysis showed that Δ-sCD27 was associated with PFS and TTP in HCC patients,and Δ-sCD27 was an inde-pendent predictor of OS.More HCC patients with Δ-sCD27 ≥2.63％had BCLC stage C/D.Kaplan-Meier curve analysis showed that HCC patients with Δ-sCD27 ≥2.63％had significant shorter OS(Log-rank x2=14.499,P＜0.001),PFS(Log-rank x2=7.274,P=0.007)and TTP(Log-rank x2=8.605,P=0.003).[Conclusion]Δ-sCD27 ≥2.63％may indicate a poor survival prognosis of advanced HCC patients after ICIs treatment,and can evaluate the efficacy of ICIs treatment by monitoring plasma sCD27 level.
NETL
NSTL
万方数据
